Until recently, psoriasis treatment was focused primarily on managing acute dermatological symptoms. However, psoriasis is now regarded as a chronic systemic inflammatory condition and long-term systemic maintenance therapy is recognised as the preferred method of clinical management. Greater understanding of immunological pathways involved in psoriasis has led to the development of targeted psoriasis treatments (Nograles et al., 2010; Nast et al., 2012; Boehncke & Boencke, 2014).
A systematic literature review confirms that adherence rates in psoriasis patients are suboptimal regardless of type of treatment or disease severity and highlights the need to improve patient compliance and satisfaction with treatment (Belinchon et al., 2016).
Traditional systemic antipsoriatic agents and interferon were most frequently discontinued due to adverse events (AEs), whilst all other biologics were most frequently discontinued due to lack of efficacy with respect to cutaneous lesions (Arnold et al., 2016).
Patients' preferences should be taken into account in the treatment decision-making process in order to improve patients' adherence and ultimately improve clinical outcomes (Belinchon et al., 2016).